Table 1

Characteristics of the study populations of the 31 articles

Article	PROMs described	n	Age (years)	Female (%)	RF+ (%)	Disease duration	Baseline disease activity
Boone 2015 SpringerPlus66	RAPID3	150	59.7 (10.8)	67	NR	12.2 (9.1) years	3.4 (1.4)
Che 2016 Clin Exp Rheum67	RAPID3	677	48.6 (12.3)	77.4	54.4	3.41 (1.64) months	5.0 (1.2)*
Kim 2014 Rheum Int69	RAPID3	400	55.4 (10.9)	87.0	91.7	7.6 (7.0) years	3.4 (1.1)
Kumar 2017 Ind J Med Res70	RAPID3	100	42.1 (11.6)	82	NR	6.0 (6.0–12.00)† months	7 (6–7)†
Munoz 2016 Clin Rheum71	RAPID3	119	61 (14)	77.3	NR	14 (5–21)† years	3.8 (2.7–5.1)†
Qorolli 2017 Clin Rheum72	RAPID3	68	53.5 (11.6)	85.3	NR	9.6 (7.9) years	5.9 (1.3)
Walker 2017 Rheum74	RAPID3, RAPID4	80	57.3 (44.9–65.9)†	58.8	NR	4.5 (1.1–9.5)† years	2.4 (1.9–3.5)†‡
Yokogawa 2015 Mod Rheum75	RAPID3	348	65.2 (12.1)	78.7	NR	11.4 (10.5) years	3.09 (1.22)
Salaffi 2015 Biomed Res Int73	PRO-CLARA	303	56.9 (9.9)	80.8	NR	5.9 (3.9) years	18.407 (7.2233)§
Katz 2018 ACR68	RADAI	96	54.8 (13.4)	87.5	NR	14.8 (12.3) years	NR
Bossert JBSPIN 201145	RADAI5, RAPID3	200	56.9 (11.5)	75.5	78	12.8 (8.3) years	3.61 (1.43)
Castrejon J Clin Rheum 201346	RAPID3	39	56.8 (13.9)	90	NR	3.5 (NR) years	NR
Choy A&R 200847¶	PDAS2	582	59.9 (20-90)**	78	80	9.3 (0–54)** years	NR
Fransen Rheum 200049	RADAI	584	59 (12)	71.9	69	8 (3–15)† years	4.3 (1.4)*
Fransen A&R 200148††	RADAI	92	52 (13)	83	87	9 (4–14)† years	4.3 (1.4)*
Fujiwara Mod Rheum 201350	RAPID3	250	59.3 (14.0)	78.4	NR	10.35 (9.83) years	NR
Houssien Rheum 199951	RADAI	100	57.7 (12.2)	78	NR	11.5 (8.3) years	4.24 (1.3)*
Leeb J Rheum 200852	RADAI, RADAI5	169	57 (19-78)**	79.9	50	7.2 (0.2–46.0)** years	3.51 (0.28-6.67) and 3.19 (1.21–5.83)‡
Leeb JBSPIN 200953	RAPID3, RADAI5	108	59.5 (24-87)‡‡	77.8	54	NR	2.95 (0.43-6.24)‡‡
Pincus ACR 201154§§	RAPID3	982	52.0 (11.6)	83.2	81.9	6.2 (4.3) years	6.9 (4.3-9.1)‡‡
Salaffi CER 201059¶¶	PRO-CLARA, RAPID3, RADAI	443	57.5 (11.6)	81.5	77	5.7 (6.3) years	3.94 (2.04)
Rintelen J Rheum 201357	RADAI5	705	62.7 (13.4)	75.9	54.4	97.3 (98.0) months	3.31 (1.37)***
Wolfe J Rheum 200565	PAS, PAS-II, RADAI	9078	62.2 (12.6)	78.2	NR	16.2 (10.9) years	NR
Pincus J Rheum 200855	RAPID3, RAPID4	285	57.4 (14.6)	73.0	NR	9.7 (9.0) years	3.4 (1.7)
Salaffi CER 201258	PRO-CLARA, RAPID3, RADAI, PAS	191	56.6 (12.2)	82.7	NR	5.1 (5.5) years	6.02 (1.15) and 4.38 (0.92)*
Stucki A&R 199561	RADAI, RADAI-SF	55	60 (14.6)	62	NR	5.1 (1.3–10.7)† years	3.1 (1.6–7.8)††††
Sullivan J Rheum 201062	RADAI, GAS	740	57.06 (13.7)	83.0	63.8	14.25 (12.3) years	4.05 (1.5)‡
Uhlig ARD 200963	RAPID3, RADAI	28	61.1 (6.2)	64	64	16.6 (10.4) years	3.12 (1.27)
Veehof ARD 200864	RADAI, RADAI-SF	191	54.4 (13.3)	71	NR	7.0 (3.0–17.0)† years	5.42 (1.07)
Pincus ACR 201056	RAPID3	200	53.4 (16.2)	81.0	NR	11.6 (10.8) years	3.7 (1.5)
Singh Clin Rheum 201260	RAPID3	200	42.2 (NR)	83	NR	4.9 (NR) years	5.2 (1.6)

For age, disease duration and baseline disease activity, values are mean (SD) unless noted otherwise. Baseline disease activity is DAS28-ESR-4v unless noted otherwise.
*DAS28-ESR-3v.
†Median (IQR).
‡DAS28-CRP-4v.
§CDAI.
¶Details on age, percentage female, percentage RF+ and disease duration pooled across the three populations listed separately.
**Mean (range).
††Details on baseline disease activity pooled across the Nonflare and Flare groups listed separately.
‡‡Median (range).
§§Details on age, percentage female, percentage RF+, disease duration and baseline disease activity pooled across the three populations listed separately defined in separate article.83
¶¶Details on age, percentage female, percentage RF+ and disease duration pooled across the two populations listed separately.
***DAS28, no further information provided.
†††Modified DAS, defined in separate article.84
NR, not reported; RF+, rheumatoid factor positive.